ME

MEI Pharma

- NASDAQ:MEIP
Last Updated 2024-04-23

LinkedIn Profile

Access MEI Pharma historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:meip 1065551 Apr 21st, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 20th, 2024 11:45PM Apr 20th, 2024 11:45PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 20th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 19th, 2024 11:43PM Apr 20th, 2024 05:18PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 19th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 18th, 2024 11:50PM Apr 18th, 2024 11:50PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 18th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 17th, 2024 11:58PM Apr 18th, 2024 06:38PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 17th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 16th, 2024 11:41PM Apr 17th, 2024 03:03PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 16th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 15th, 2024 11:37PM Apr 16th, 2024 11:20AM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 15th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 14th, 2024 11:32PM Apr 15th, 2024 05:01PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 14th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 13th, 2024 11:21PM Apr 13th, 2024 11:21PM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 13th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 12th, 2024 11:12PM Apr 13th, 2024 11:46AM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services
nasdaq:meip 1065551 Apr 12th, 2024 12:00AM MEI Pharma 4.1K 142.00 Open Apr 11th, 2024 11:17PM Apr 12th, 2024 08:41AM MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. Open Open 11455 El Camino Real San Diego CA US 92130 MEI Pharma Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.